Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. The company has also worked hard to diversify its pipeline. The stock is worth the premium. And that's before we get into ...

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its “Buy” rating on Eli Lilly stock.

Key Points Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a ...

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years.

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now.

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

SYRACUSE — At last year’s inaugural “Famous Hoosiers” program Richard Gunderman made a moving and very well received presentation about Hoosier legend John Wooden.